Zydus Lifesciences Ltd. Market Research Report

Company Overview

Name

Zydus Lifesciences Ltd.

Mission

The company's mission emphasizes delivering care and nurturance for patients backed by innovation, science, and cutting-edge technology.

Founding

Zydus Lifesciences was originally founded as Cadila Healthcare Ltd. It has a history spanning over 70 years.

Key People

• Mr. Pankaj R. Patel: Chairman

• Dr. Sharvil Patel: Managing Director

Headquarters

Ahmedabad, India

Number of Employees

Over 26,000 employees

Revenue

No information is available.

Known For

Zydus is known for its innovation in the pharmaceutical industry and its global reach. It ranks 4th in the Indian pharmaceutical sector and is known for developing various pharmaceutical solutions, such as prescription drugs and vaccines.

Products

Product Offerings

Zydus offers a variety of pharmaceutical products, including:

1. OxemiaTM (Desidustat):

• Description: A first-of-its-kind oral treatment in India.

• Use: Alternative to injectable erythropoietin-stimulating agents for anemia associated with Chronic Kidney Disease (CKD).

2. Exemptia:

• Description: The world's first biosimilar of Adalimumab.

• Use: Treats autoimmune disorders, providing a new lease of life to Indian patients of inflammatory arthritis.

3. Vaxiflu-4:

• Description: India’s 1st Tetravalent Inactivated Influenza Vaccine.

• Protection from: Four influenza viruses - H1N1, H3N2, Type B (Brisbane), and Type B (Phuket).

4. TwinrabTM:

• Description: A breakthrough innovation in rabies PEP.

• Components: Contains Docaravimab and Miromavimab, a world-first cocktail of Novel Rabies Monoclonal Antibodies (mAbs).

5. Lipaglyn:

• Description: A novel drug to treat diabetic dyslipidemia.

• Significance: The first NCE from an Indian research pipeline to move from the lab to the market.

Key Features

• Innovative and patient-centric approach

• Commitment to science and healthcare solutions

• Presence in both regulated and emerging markets

Recent Developments

Recent Approvals and Partnerships

1. USFDA Approvals:

• Final approval for Lenalidomide Capsules (5 mg, 10 mg, 15 mg, 25 mg) - 13 September 2022.

• Final approval and 180 days of shared exclusivity for Cariprazine Capsules - 12 September 2022.

2. Partnerships:

• In-licensed a critical drug for CKD patients from Pharmacosmos of Denmark - 9 September 2022.

3. Research Advancements:

• Announced positive Phase 2 Proof-of-Concept of NLRP3 inhibitor ZYIL1 for patients with Cryopyrin Associated Periodic Syndrome (CAPS) - 7 September 2022.

New Products

There are no specific mentions of new separate product launches within the data provided.

New Features

• Zydus focuses on adding new features to existing products through innovative research and partnerships, such as the introduction of new biosimilar drugs.

New Partnerships

• Collaboration with Pharmacosmos for in-licensing essential drugs for CKD patients.

Conclusion

Zydus Lifesciences Ltd. stands out in the pharmaceutical industry with its rich tradition of innovation and global presence. With ongoing expansions in research and development, strategic partnerships, and significant pharmaceutical advancements, Zydus continues to build its brand as a care-centric, global healthcare solutions provider.